ClinicalTrials.gg
CompletedNCT03352726V712-103Updated Jul 26, 2019

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

A Phase 1 interventional study of DBV712 IHRP in Peanut Allergy, sponsored by DBV Technologies. Completed at 2 sites in United States. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-07-26.

Sponsored by DBV Technologies · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.

Enrollment
10th of 10
27 · median 105
Started
2017
the only one that year
Phase 1
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
5 of 10
DBV Technologies

Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 5th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →

About palforzia

Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing palforzia in Peanut Hypersensitivity as a file.
02

Study summary

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

03

Conditions studied

  • Peanut Allergy

Keywords

  • EPIT
  • Epicutaneous
  • Immunotherapy
  • Viaskin
04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female subjects aged between 12-50 years
  • Physician-diagnosed peanut allergy
  • Subject currently following a strict peanut-free diet
  • Documented history of positive test to peanut-specific IgE (ImmunoCAP system) >0.7 kU/L
  • Positive peanut SPT with a largest wheal diameter ≥ 8 mm

Main Exclusion Criteria:

  • Uncontrolled asthma
  • Peanut allergen immunotherapy whatever the route, either ongoing or previously started and having lasted more than one month (>30 days)
  • Topical use of within the past 14 days prior to the Screening SPT
  • Inability to discontinue short-acting antihistamines
  • Atopic dermatitis, eczema or urticaria on the areas to be tested
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    DBV712 Solution for Skin Prick Test

    DBV712 In-House Reference Skin Prick Test preparation

    Drug: DBV712 IHRP

Interventions

06

What researchers measure

Primary outcomes

  1. Biological potency of the In-House Reference peanut proteins extract (DBV712-IHRP) in arbitrary Biological Units (BU)

    Time frame: 1 day to 2 weeks

Secondary outcomes

  1. Adverse Events (AEs), Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)

    Time frame: Throughout the study (1 day to 2 weeks)

07

Study locations

2 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2018, 7 months.

Of 14 phase 1 interventional studies under Peanut Hypersensitivity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 52. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2017
First posted
Nov 24, 2017
StartActual
Nov 24, 2017
Primary completionActual
Jun 29, 2018
CompletionActual
Jun 29, 2018
Last update
Jul 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03352726
Lead sponsor
DBV Technologies
Responsible party
Sponsor
First posted
Nov 24, 2017
Start date
Nov 24, 2017
Primary completion
Jun 29, 2018
Completion
Jun 29, 2018
Last update
Jul 26, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palforzia

Start the discussion